NEWS | BEAM Alliance


Nosopharm and Evotec enter into collaboration to accelerate development of novel antibiotics

  • New partnership to advance Nosopharm’s lead candidate to clinical stage and develop second drug candidate
  • NOSO-502 could be first novel antibiotic class against Enterobacteriace infections to enter clinics in forty years

Lyon, France and Hamburg, Germany, July 3, 2019 – Nosopharm, a company dedicated to the research and development of new anti-infective drugs, and Evotec SE, a drug discovery and development company, today announce their partnership aimed at advancing Nosopharm’s lead candidate, NOSO-502, to the clinical stage, as well as developing a second-generation Odilorhabdin drug candidate. Financial terms of the agreement were not disclosed.

Full PR available here